Antitumor activity of SK-7041, a novel histone deacetylase inhibitor, in human lung and breast cancer cells

被引:0
|
作者
Lee, Keun-Wook
Kim, Jee Hyun
Park, Jung-Hyun
Kim, Hwang-Phill
Song, Sang-Hyun
Kim, Sang Gyun
Kim, Tai Young
Jong, Hyun-Soon
Jung, Kyung Hae
Im, Seock-Ah
Kim, Tae-You
Kim, Noe Kyeong
Bang, Yung-Jue
机构
[1] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 110744, South Korea
[2] Seoul Natl Univ, Coll Med, Canc Res Inst, Seoul 110744, South Korea
[3] Seoul Natl Univ, Bundang Hosp, Dept Internal Med, Songnam, South Korea
[4] Seoul Natl Univ Hosp, Dept Internal Med, Seoul 110744, South Korea
[5] Natl Canc Ctr, Res Inst Hosp, Goyang 411769, Gyeonggi, South Korea
关键词
SK-7041; histone deacetylase inhibitor; lung cancer; breast cancer; apoptosis;
D O I
暂无
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: A class of synthetic histone deacetylase (HDAC) inhibitors, which are hybrids of trichostatin A and MS-275 were previously developed. In this study, the antitumor effects of SK-7041, one of those novel HDAC inhibitors, was evaluated on lung and breast cancer cell lines. Materials and Methods: Human lung and breast cancer cells, as well as normal human bronchial epithelial (NHBE) cells were treated with SK-7041, and results were compared with those of cells treated with suberoylanilide hydroxamic acid (SAHA). Results: SK-7041 induced time-dependent histone hyperacetylation and showed more potent cytotoxicity than SAHA in cancer cells. These antiproliferative effects of SK-7041 were due to apoptotic cell death caused by G21M-phase arrest and to a lesser extent to G1 arrest. Moreover, SK-7041 inhibited cancer cell proliferation more selectively than NHBE cell proliferation. Conclusion: These results suggest that SK-7041 may have potential anticancer activity.
引用
收藏
页码:3429 / 3438
页数:10
相关论文
共 50 条
  • [41] The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) induces differentiation of human breast cancer cells.
    Munster, PN
    Rosen, N
    Rifkind, R
    Marks, P
    Richon, V
    CLINICAL CANCER RESEARCH, 2001, 7 (11) : 3725S - 3725S
  • [42] In vivo and in vitro antitumor activity of butyroyloxymethyl-diethyl phosphate (AN-7), a histone deacetylase inhibitor, in human prostate cancer
    Rephaeli, A
    Blank-Porat, D
    Tarasenko, N
    Entin-Meer, M
    Levovich, I
    Cutts, SM
    Phillips, DR
    Malik, Z
    Nudelman, A
    INTERNATIONAL JOURNAL OF CANCER, 2005, 116 (02) : 226 - 235
  • [43] Anticancer activity of the novel histone deacetylase inhibitor, MPT0G028, in human colorectal cancer cells in vitro and in vivo
    Lee, Chia-Hua
    Chen, Chun-Han
    Pan, Shiow-Lin
    Teng, Che-Ming
    ACTA PHARMACOLOGICA SINICA, 2013, 34 : 8 - 8
  • [44] Modulation of sensitivity to doxorubicin by the histone deacetylase inhibitor sodium butyrate in breast cancer cells
    Louis, M
    Rosato, RR
    Battaglia, E
    Néguesque, A
    Lapotre, A
    Grant, S
    Bagrel, D
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2005, 26 (06) : 1569 - 1574
  • [45] Valproic acid, a histone deacetylase inhibitor, induces apoptosis in breast cancer stem cells
    Aztopal, Nazlihan
    Erkisa, Merve
    Erturk, Elif
    Ulukaya, Engin
    Tokullugil, Asuman Hatice
    Ari, Ferda
    CHEMICO-BIOLOGICAL INTERACTIONS, 2018, 280 : 51 - 58
  • [46] Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
    Chandra R Tate
    Lyndsay V Rhodes
    H Chris Segar
    Jennifer L Driver
    F Nell Pounder
    Matthew E Burow
    Bridgette M Collins-Burow
    Breast Cancer Research, 14
  • [47] Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat
    Tate, Chandra R.
    Rhodes, Lyndsay V.
    Segar, H. Chris
    Driver, Jennifer L.
    Pounder, F. Nell
    Burow, Matthew E.
    Collins-Burow, Bridgette M.
    BREAST CANCER RESEARCH, 2012, 14 (03)
  • [48] Diverse and unique cellular effects of SK-7068, a novel histone deacetylase inhibitor
    Park, JH
    Jung, YJ
    Lee, JW
    Jong, HS
    Kim, TY
    Bang, YJ
    EUROPEAN JOURNAL OF CANCER, 2002, 38 : S96 - S97
  • [49] Antitumor activity of a novel antiestrogen (Analog II) on human breast cancer cells
    Jain, PT
    Rajah, TT
    Pento, JT
    ANTI-CANCER DRUGS, 1997, 8 (10) : 964 - 973
  • [50] The efficacy of a histone deacetylase inhibitor in combination with a MEK inhibitor in lung cancer cells harboring RAS mutations
    Yamada, Tadaaki
    Amann, Joseph M.
    Tanimoto, Azusa
    Taniguchi, Hirokazu
    Shukuya, Takehito
    Yano, Seiji
    Takayama, Koichi
    Carbone, David P.
    CANCER RESEARCH, 2018, 78 (13)